GENEVA--(BUSINESS WIRE)--Endosense, a medical technology company focused on improving the efficacy, safety and reproducibility of catheter ablation for the treatment of cardiac arrhythmias, has announced the release of 12-month data from the TOCCATA (TOuCh+ for CATheter Ablation) study that further reinforce the potential of the TactiCath force-sensing ablation catheter to improve clinical outcomes in the treatment of cardiac arrhythmia by catheter ablation. The data was reported in a clinical abstract at Heart Rhythm 2010, the Heart Rhythm Society’s 31st Annual Scientific Sessions in Denver, May 12 – 15.
